Topotecan liposomal (Fujifilm Pharmaceuticals USA)

托泊替康脂质体 (Fujifilm Pharmaceuticals USA)

Report date: 2025/06/26 20:00:07

Base Information

Drug NameTopotecan liposomal (Fujifilm Pharmaceuticals USA)
Drug Alias NameDihydrosphingomyelin based liposomal topotecanFF-10850
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursCarcinoma, Merkel Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFujifilm Pharmaceuticals U.S.A. Inc
China Registration ClassN/A

Develop Information

Active CompaniesFujifilm Pharmaceuticals U.S.A. Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Merkel Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A